Abstract：Objective: To analyze the relationship between the changes of coagulation parameters and the severity of the disease and adverse pregnancy outcomes in patients with pregnancy induced hypertension disease (PIH). Methods: A total of 199 hospitalized patients with pregnancy induced hypertension in late pregnancy from May 2019 to May 2021 were retrospectively selected as the study group: 55 cases of pregnancy induced hypertension, 75 cases of pre eclampsia, 69 cases of severe pre eclampsia, and 59 healthy pregnant women of the same age and week as the control group. The anticoagulation related parameters of each group and the adverse pregnancy outcome rate of the study group were statistically analyzed. Results: There were significant difference in 9 parameters between the hypertensive group during pregnancy and the control group (P<0.05,P<0.01), and there were significant difference in activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), platelet count (PLT), mean platelet volume (MPV), and platelet hematocrit (PCT) between preeclampsia and severe preeclampsia and the control group (P<0.05,P<0.01). Spearman showed that FIB was positively correlated with them (P<0.01), MPV, APTT, TT, PLT, PCT were negatively correlated with them (P<0.01). With the aggravation of the disease, the adverse pregnancy outcome rate increased, P<0.01, and the difference was statistically significant. Conclusion: FIB, MPV, APTT, TT and PLT have potential predictive value for disease severity and adverse outcome.
王国增, 王新, 李丽, 朱丽莉, 鲁煜红, 朱潮旭, 孙国宗, 刘志强. 孕晚期妊娠期高血压疾病患者止凝血参数与妊娠不良结局的相关性分析[J]. 河北医学, 2023, 29(8): 1344-1348.
WANG Guozeng, WANG Xin, LI Li, et al. Correlation Analysis of Anticoagulation Parameters and Adverse Pregnancy Outcomes in Patients with Hypertensive Diseases in Late Pregnancy. HeBei Med, 2023, 29(8): 1344-1348.
[1] 杨敏,刘明翠,杨海凤.妊高症产妇临产前凝血系统的变化对妊娠结局的影响[J].贵州医药,2019,43(6):913-914. [2] 谢幸,孔北华,段涛等.妇产科学[M].第9版.人民卫生出版社,2018.83-84. [3] 赵花,田玲,沈禾,王倩,单婉君,吴梦丽.凝血功能指标及血小板参数与子痫前期的相关性研究[J].蚌埠医学院学报,2020,45(7):883-887. [4] 陈波,张加勤,洪国粦.妊娠期高血压疾病患者凝血及抗凝功能的变化[J].中国妇幼保健,2021,36(1):33-35. [5] 王霞,唐晓慧,张金保.血清凝血指标表达水平与妊娠期高血压疾病的相关性[J].中国计划生育学杂志,2022,30(6):1340-1343. [6] 周立娜,张蕾,孙晓娜,等.妊娠期高血压疾病患者凝血功能指标、血小板参数和血清钙离子浓度的变化及意义[J].河北医药,2022,44(12):1851-1854. [7] Abdul Razak,Waseemoddin Patel,Naveed Durrani,etal.Neonatal respiratory outcomes in pregnancy induced hypertension introducing a novelindex[J].The Joumal of Maternal-Fetal& Neonatal Medicine,2020,33(4):625-632. [8] 曹均,越小丽.妊娠期凝血功能指标检测在子痫前期诊断治疗中的临床意义[J].国际检验医学杂志,2021,42(11):1401-1403,1408. [9] Valiton Vivian et al.Obstetrical and postpartum complications in women with hereditary fibrinogen disorders:a systematic literature review[J].Haemophilia:the official journal of the World Federation of Hemophilia,2019,25(5):747-754. [10] 吴群尔,陈慧芬.HELLP综合征产妇产前出凝血功能在产后出血和胎儿不良结局预测中的价值[J].检验医学,2022,37(6):547-550. [11] 闫琼琼.孕妇妊娠期高血压疾病与血小板、凝血功能的相关性研究[J].血栓与止血学,2018,24(2):243-245.
2023, Vol. 29 
冀公网安备13080202000677号